Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Tiziana Life Sciences Ltd - Common Shares
(NQ:
TLSA
)
0.9799
+0.0106 (+1.09%)
Streaming Delayed Price
Updated: 9:33 AM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tiziana Life Sciences Ltd - Common Shares
< Previous
1
2
3
4
5
6
Next >
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Today 7:00 EDT
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
July 31, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
July 22, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
June 25, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
June 15, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
May 28, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
May 21, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
May 19, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
May 14, 2026
Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System Atrophy
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
April 16, 2026
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated “brain fog”.
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
April 14, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
April 01, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
February 25, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
January 20, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
January 16, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
January 16, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
January 09, 2026
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
December 29, 2025
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
December 19, 2025
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
December 17, 2025
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
December 17, 2025
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
December 15, 2025
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering
December 15, 2025
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial
December 12, 2025
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
December 02, 2025
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
November 25, 2025
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
November 13, 2025
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
November 04, 2025
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
October 29, 2025
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
September 30, 2025
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
